Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.67 Consensus Price Target from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $7.6667.

Several equities research analysts have weighed in on NMRA shares. Leerink Partners began coverage on Neumora Therapeutics in a report on Monday, January 12th. They set an “outperform” rating and a $8.00 price target on the stock. Mizuho set a $6.00 price objective on Neumora Therapeutics in a research note on Monday, January 5th. Guggenheim reissued a “buy” rating and set a $14.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, March 31st. William Blair upgraded shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 31st.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $2.25 on Wednesday. The firm has a 50 day moving average of $2.67 and a two-hundred day moving average of $2.36. The stock has a market capitalization of $411.05 million, a PE ratio of -1.55 and a beta of 3.08. The company has a quick ratio of 5.87, a current ratio of 5.87 and a debt-to-equity ratio of 0.52. Neumora Therapeutics has a 52 week low of $0.61 and a 52 week high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, research analysts predict that Neumora Therapeutics will post -0.99 EPS for the current fiscal year.

Insider Activity at Neumora Therapeutics

In other news, insider Paul L. Berns sold 9,819 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the sale, the insider directly owned 7,395,185 shares in the company, valued at approximately $25,957,099.35. This trade represents a 0.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 23,387 shares of company stock valued at $82,647. Corporate insiders own 26.80% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. AlphaCore Capital LLC increased its holdings in shares of Neumora Therapeutics by 89.1% in the 3rd quarter. AlphaCore Capital LLC now owns 638,784 shares of the company’s stock valued at $1,163,000 after acquiring an additional 301,017 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Neumora Therapeutics by 10.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock valued at $117,000 after purchasing an additional 6,233 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in Neumora Therapeutics during the third quarter worth approximately $108,000. Brookstone Capital Management purchased a new stake in shares of Neumora Therapeutics during the 3rd quarter worth approximately $42,000. Finally, Henson Edgewater Management LLC purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth approximately $292,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.